RBC Capital Reiterates Sector Perform on Design Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev reiterated a 'Sector Perform' rating on Design Therapeutics (DSGN) and maintained a $4 price target.
March 20, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Design Therapeutics maintains a 'Sector Perform' rating and a $4 price target from RBC Capital.
The reiteration of the 'Sector Perform' rating and maintenance of the $4 price target by RBC Capital suggests a neutral outlook on Design Therapeutics. This indicates that the analyst sees the company performing in line with the sector without significant short-term price movements expected.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90